Australia Red Biotechnology Market Size & Outlook
Australia red biotechnology market, 2018-2030 (US$M)
Related Markets
Australia red biotechnology market highlights
- The Australia red biotechnology market generated a revenue of USD 16,335.3 million in 2023 and is expected to reach USD 44,891.4 million by 2030.
- The Australia market is expected to grow at a CAGR of 15.5% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Gene Therapy Products is the most lucrative product segment registering the fastest growth during the forecast period.
Red biotechnology market data book summary
| Market revenue in 2023 | USD 16,335.3 million |
| Market revenue in 2030 | USD 44,891.4 million |
| Growth rate | 15.5% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Gene Therapy Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal Models, Molecular Diagnostics |
| Key market players worldwide | Merck KGaA, Roche Holding AG ADR, Pfizer Inc, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Gilead Sciences Inc, Biogen Inc, Amgen Inc, Bristol-Myers Squibb Co, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, Australia accounted for 3.3% of the global red biotechnology market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan red biotechnology market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 54,951.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Red Biotechnology Market Scope
Red Biotechnology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia red biotechnology market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to red biotechnology market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 49.72% in 2023. Horizon Databook has segmented the Australia red biotechnology market based on monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, cell-based immunotherapy products, gene therapy products, cell therapy products, tissue-engineered products, stem cells, cell culture, viral vector, enzymes, kits and reagents, animal models, molecular diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Australia red biotechnology market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia red biotechnology market databook
-
Our clientele includes a mix of red biotechnology market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia red biotechnology market , including forecasts for subscribers. This country databook contains high-level insights into Australia red biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia red biotechnology market size, by product, 2018-2030 (US$M)
Australia Red Biotechnology Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
